{"id":55168,"date":"2026-01-22T20:44:34","date_gmt":"2026-01-22T12:44:34","guid":{"rendered":"https:\/\/flcube.com\/?p=55168"},"modified":"2026-01-22T20:44:36","modified_gmt":"2026-01-22T12:44:36","slug":"astrazenecas-imfinzi-wins-china-approval-for-endometrial-cancer-securing-seventh-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55168","title":{"rendered":"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication"},"content":{"rendered":"\n

AstraZeneca<\/strong> (AZ, NASDAQ:\u202fAZN<\/a>) announced that Imfinzi (durvalumab)<\/strong> has been officially approved in China for use in combination with carboplatin and paclitaxel<\/strong>, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer<\/strong>. This marks the seventh indication<\/strong> approved for durvalumab in China.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>AstraZeneca plc (NASDAQ:\u202fAZN)<\/td><\/tr>
Drug<\/strong><\/td>Imfinzi (durvalumab)<\/td><\/tr>
Approval<\/strong><\/td>China NMPA<\/td><\/tr>
**Indication<\/td>First\u2011line dMMR primary advanced or recurrent endometrial cancer<\/td><\/tr>
**Regimen<\/td>Carboplatin + paclitaxel + durvalumab, followed by durvalumab maintenance<\/td><\/tr>
**Study<\/td>DUO-E (Phase\u202fIII)<\/td><\/tr>
**Key Data<\/td>Asian patients accounted for ~30% of study population<\/td><\/tr>
**Mechanism<\/td>Humanized PD\u2011L1 monoclonal antibody<\/td><\/tr>
**First Approval in China<\/td>2019 (unresectable Stage\u202fIII NSCLC post\u2011cCRT)<\/td><\/tr>
**Total China Indications<\/td>7 (including endometrial cancer)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
    \n
  • Mechanism of Action:<\/strong> Durvalumab<\/strong> blocks PD\u2011L1 interaction with PD\u20111 and CD80, restoring anti\u2011tumor T\u2011cell immunity<\/li>\n\n\n\n
  • Clinical Validation:<\/strong> First approved in China in 2019<\/strong> for unresectable Stage\u202fIII NSCLC<\/strong> post\u2011concurrent chemoradiotherapy, becoming the first immunotherapy<\/strong> for that indication<\/li>\n\n\n\n
  • DUO-E Study:<\/strong> Demonstrated clear PFS benefit<\/strong> for durvalumab + chemotherapy vs. chemotherapy alone in dMMR endometrial cancer<\/li>\n\n\n\n
  • Asian Representation:<\/strong> Nearly 30% Asian patients<\/strong> in DUO-E enhances clinical relevance for China population<\/li>\n<\/ul>\n\n\n\n

    Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
    Parameter<\/th>China Endometrial Cancer Market<\/th>dMMR Segment<\/th><\/tr><\/thead>
    Incidence (2026E)<\/strong><\/td>82,000 new cases<\/td>16,400 (20% dMMR)<\/td><\/tr>
    Advanced\/Recurrent at Diagnosis<\/strong><\/td>24,600<\/td>4,920<\/td><\/tr>
    Current Standard<\/strong><\/td>Chemotherapy alone (carboplatin + paclitaxel)<\/td><\/td><\/tr>
    PD\u20111\/PD\u2011L1 Penetration<\/strong><\/td><15%<\/td><5%<\/td><\/tr>
    Imfinzi Addressable Market<\/strong><\/td>\u2013<\/td>4,920<\/td><\/tr>
    Annual Cost (Est.)<\/strong><\/td>\u2013<\/td>$35,000\u201145,000<\/td><\/tr>
    Peak Market Share (2032E)<\/strong><\/td>12%<\/td>25%<\/td><\/tr>
    Peak Revenue (2032E)<\/strong><\/td>\u00a51.8\u202fbillion<\/td>$55\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Key Competitors:<\/strong><\/p>\n\n\n\n

      \n
    • Keytruda (pembrolizumab)<\/strong> \u2013 Approved for MSI\u2011H\/dMMR endometrial cancer in US\/EU, not yet in China<\/strong> for this indication<\/li>\n\n\n\n
    • Opdivo (nivolumab)<\/strong> \u2013 Similar status, limited endometrial presence in China<\/li>\n\n\n\n
    • Imfinzi<\/strong> \u2013 First PD\u2011L1 inhibitor<\/strong> approved for dMMR endometrial cancer in China; 7th indication<\/strong> strengthens oncology portfolio<\/li>\n<\/ul>\n\n\n\n

      Strategic Positioning<\/h2>\n\n\n\n
        \n
      • Manufacturing:<\/strong> AstraZeneca\u2019s Wuxi, China biologics facility<\/strong> (capacity 80,000\u202fL) will produce Imfinzi for domestic market; fully GMP\u2011certified<\/strong><\/li>\n\n\n\n
      • Commercial Reach:<\/strong> 3,500\u2011person oncology sales force<\/strong> established across China; cross\u2011detailing capability<\/strong> for endometrial cancer leverages existing gynecologic oncology relationships<\/li>\n\n\n\n
      • Reimbursement Pathway:<\/strong> Eligible for NRDL Category\u202f1 negotiation<\/strong> in 2026; priority review status<\/strong> (already granted) accelerates access<\/li>\n\n\n\n
      • Pipeline Synergy:<\/strong> Success validates durvalumab + chemotherapy backbone<\/strong> for other dMMR solid tumors<\/strong> (gastric, biliary)<\/li>\n<\/ul>\n\n\n\n

        Forward\u2011Looking Statements<\/strong>
        This brief contains forward\u2011looking statements regarding market penetration, revenue forecasts, and competitive dynamics for Imfinzi in China. Actual results may differ due to NRDL pricing negotiations, competitive entry, and clinical adoption rates.<\/p>\n","protected":false},"excerpt":{"rendered":"

        AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,770,16,871,18,15],"class_list":["post-55168","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-az","tag-cancer","tag-nasdaq-azn","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"\nAstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This marks the seventh indication approved for durvalumab in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55168\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This marks the seventh indication approved for durvalumab in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55168\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T12:44:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T12:44:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55168#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55168\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication\",\"datePublished\":\"2026-01-22T12:44:34+00:00\",\"dateModified\":\"2026-01-22T12:44:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55168\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"Cancer\",\"NASDAQ: AZN\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55168#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55168\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55168\",\"name\":\"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T12:44:34+00:00\",\"dateModified\":\"2026-01-22T12:44:36+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This marks the seventh indication approved for durvalumab in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55168#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55168\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55168#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication - Insight, China's Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This marks the seventh indication approved for durvalumab in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55168","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication","og_description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This marks the seventh indication approved for durvalumab in China.","og_url":"https:\/\/flcube.com\/?p=55168","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T12:44:34+00:00","article_modified_time":"2026-01-22T12:44:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55168#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55168"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication","datePublished":"2026-01-22T12:44:34+00:00","dateModified":"2026-01-22T12:44:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55168"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","Cancer","NASDAQ: AZN","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55168#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55168","url":"https:\/\/flcube.com\/?p=55168","name":"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T12:44:34+00:00","dateModified":"2026-01-22T12:44:36+00:00","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that Imfinzi (durvalumab) has been officially approved in China for use in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy maintenance, for the first\u2011line treatment of adult patients with mismatch repair deficient (dMMR) primary advanced or recurrent endometrial cancer. This marks the seventh indication approved for durvalumab in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55168#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55168"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55168#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca\u2019s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55168"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55168\/revisions"}],"predecessor-version":[{"id":55169,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55168\/revisions\/55169"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}